Literature DB >> 4015694

Cyclopentenyl cytidine analogue. An inhibitor of cytidine triphosphate synthesis in human colon carcinoma cells.

R I Glazer, M C Knode, M I Lim, V E Marquez.   

Abstract

The mechanism of action of the cyclopentenyl analogue of cytidine, cCyd, was investigated in human colon carcinoma cell line HT-29. Upon exposure of cells to 10(-6)M cCyd, cell viability was reduced to 20% of control, whereas cytocidal activity was not present after 2 hr of drug exposure. Cell lethality was partially reversible by Urd, Cyd or dCyd at 10(-6)M cCyd, and fully reversible by these nucleosides at 2.5 X 10(-7)M cCyd. The incorporation of [14C]dThd and [3H]Urd into DNA and RNA was inhibited by 50% by exposure for 2 hr to 2.5 X 10(-7) and 1.5 X 10(-6)M cCyd respectively. Upon 24 hr of drug exposure, the IC50 for RNA synthesis was reduced 2.5-fold, whereas DNA synthesis was almost totally inhibited. cCyd produced a rapid and preferential reduction of CTP synthesis with a half-life of 1 hr at 10(-6)M drug. The IC50 of cCyd for reducing CTP concentrations after 2 hr of drug exposure was 4 X 10(-7)M. Concomitant with the reduction of CTP levels was the inhibition of transcription of rRNA and, to a lesser extent, tRNA, without changes in the processing nucleolar RNA. No changes in the size of DNA were produced following treatment with cCyd. These results indicate that cCyd is a potent and rapid inhibitor of CTP synthesis and that this effect correlates with its cytocidal activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015694     DOI: 10.1016/0006-2952(85)90539-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Introduction of a fluorine atom at C3 of 3-deazauridine shifts its antimetabolic activity from inhibition of CTP synthetase to inhibition of orotidylate decarboxylase, an early event in the de novo pyrimidine nucleotide biosynthesis pathway.

Authors:  Jan Balzarini; Federico Gago; Wim Kulik; André B P van Kuilenburg; Anna Karlsson; Matt A Peterson; Morris J Robins
Journal:  J Biol Chem       Date:  2012-06-24       Impact factor: 5.157

2.  Cyclopentenyl cytosine: interspecies predictions based on rodent plasma and urine kinetics.

Authors:  D S Zaharko; J A Kelley; J E Tomaszewski; L Hegedus; N R Hartman
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

3.  In vitro characterization of the myelotoxicity of cyclopentenyl cytosine.

Authors:  D A Volpe; D L Du; C K Grieshaber; M J Murphy
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Phase I clinical trial of continuous infusion cyclopentenyl cytosine.

Authors:  P M Politi; F Xie; W Dahut; H Ford; J A Kelley; A Bastian; A Setser; C J Allegra; A P Chen; J M Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  The pyrimidin analogue cyclopentenyl cytosine induces alloantigen-specific non-responsiveness of human T lymphocytes.

Authors:  N Nikolaeva; F J Bemelman; S-L Yong; A Verschuur; R A W van Lier; I J M ten Berge
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

6.  Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine.

Authors:  E De Clercq; R Bernaerts; Y F Shealy; J A Montgomery
Journal:  Biochem Pharmacol       Date:  1990-01-15       Impact factor: 5.858

7.  Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase.

Authors:  E De Clercq; J Murase; V E Marquez
Journal:  Biochem Pharmacol       Date:  1991-06-15       Impact factor: 5.858

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.